Chong Kun Dang Pharmaceutical (185750) - Total Liabilities
Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has total liabilities worth ₩803.02 Billion KRW (≈ $544.20 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Chong Kun Dang Pharmaceutical (185750) long-term investment share to see how much of total assets are deployed in long-term investments.
Chong Kun Dang Pharmaceutical - Total Liabilities Trend (2016–2025)
This chart illustrates how Chong Kun Dang Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Chong Kun Dang Pharmaceutical's balance sheet.
Chong Kun Dang Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dongwon F & B
KO:049770
|
Korea | ₩1.06 Trillion |
|
Zambal Spain Socimi SA
MC:YZBL
|
Spain | €87.38 Million |
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
China | CN¥4.16 Billion |
|
Beijing Advanced Digital Technology Co Ltd
SHE:300541
|
China | CN¥1.63 Billion |
|
Spearhead Integrated Marketing
SHE:300071
|
China | CN¥608.62 Million |
|
China Wuyi Co Ltd
SHE:000797
|
China | CN¥16.52 Billion |
|
Jinhe Biotechnology Co Ltd
SHE:002688
|
China | CN¥2.99 Billion |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
China | CN¥399.05 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Chong Kun Dang Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Chong Kun Dang Pharmaceutical balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chong Kun Dang Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chong Kun Dang Pharmaceutical (2016–2025)
The table below shows the annual total liabilities of Chong Kun Dang Pharmaceutical from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩793.94 Billion ≈ $538.04 Million |
+41.17% |
| 2024-12-31 | ₩562.39 Billion ≈ $381.12 Million |
-4.16% |
| 2023-12-31 | ₩586.79 Billion ≈ $397.66 Million |
+16.52% |
| 2022-12-31 | ₩503.59 Billion ≈ $341.28 Million |
+4.72% |
| 2021-12-31 | ₩480.89 Billion ≈ $325.89 Million |
+21.82% |
| 2020-12-31 | ₩394.74 Billion ≈ $267.51 Million |
+20.94% |
| 2019-12-31 | ₩326.40 Billion ≈ $221.20 Million |
+16.32% |
| 2018-12-31 | ₩280.60 Billion ≈ $190.16 Million |
+2.44% |
| 2017-12-31 | ₩273.91 Billion ≈ $185.63 Million |
-4.71% |
| 2016-12-31 | ₩287.45 Billion ≈ $194.80 Million |
-- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more